Source: BioPortfolio

Silvergate: Silvergate Pharmaceuticals announces Xatmep availability

David SalazarThe drug approved by the Food and Drug Administration in April is indicated to treat acute lymphoblastic leukemia and manage polyarticular juvenile idiopathic arthritis in pediatric patients.read more

Read full article »
Silvergate's Competitors | Silvergate's News | Silvergate's Financials
Stay up-to-date with the latest news on Silvergate Pharmaceuticals
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Neal I. Muni's photo - President & CEO of Silvergate Pharmaceuticals

President & CEO

Neal I. Muni

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Silvergate Pharmaceuticals